Trial
NCT02833506
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Fallopian Tube Carcinoma
Intervention
Laboratory Biomarker Analysis
Why stopped
production of adjuvant to be used with vaccine was discontinued by sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-01